Liposomal Bupivacaine Market [2021-2031] - Size, Share
The Liposomal Bupivacaine Market is expected to register a CAGR of 9.3% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by Type (20ml, 10ml). Futher, it is segmented based on Application (Veterinary, Human). The global analysis is further broken-down at regional level and major countries. The report offers the value in USD for the above analysis and segments.
Purpose of the ReportThe report Liposomal Bupivacaine Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Liposomal Bupivacaine Market Segmentation
Type- 20ml
- 10ml
- Veterinary
- Human
Strategic Insights
Liposomal Bupivacaine Market Growth Drivers- Added Comfort and Relief of Pain: Liposomal bupivacaine has longer analgesia compared to the traditional bupivacaine. As such, the prolonged release formulation enhances patient comfort and satisfaction, further pushing the demands in the market.
- FDA Approval and Recognition: The FDA has recently approved liposomal bupivacaine for post-surgical pain. In that respect, healthcare providers have increased its acceptance, thereby increasing its use levels in hospitals and medical settings.
- Increasing Number of Surgeries: Increasing surgeries, mainly at outpatient facilities, drive the demand for pain management solutions like liposomal bupivacaine, which enhances recovery experiences.
- Shift Towards Multimodal Analgesia: The trend is shifting towards multimodal analgesia in which bupivacaine in its liposomal formulation is used in combination with other analgesics to maximize the effects of pain management and minimize adverse side effects, enhancing patient care overall.
- More Product Development: Constant studies on the safety and efficacy of liposomal bupivacaine have led to new uses and formulations, making it more versatile in many surgical procedures and pain management protocols.
- Technological Advances: Improvements in drug delivery technologies advance the formulation and delivery properties of liposomal bupivacaine, making it an attractive choice for clinicians as well as for patients.
- Reduced Opioid-Use Options: Opioid dependence has become a significant issue, and people are looking for alternative pain management options. Liposomal bupivacaine is a non-opioid option, which is in line with this trend and hence driving the growth of the market.
- High Awareness among Healthcare Professionals: Education and awareness about the benefits of liposomal bupivacaine among the healthcare professionals are driving its adoption in practice, and hence, market growth.
- Patient-Centric Solutions: Being able to enhance recovery experiences, liposomal bupivacaine is well-positioned to meet changing patient and provider needs that are increasingly being focused on patient-centered care.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Liposomal Bupivacaine Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Liposomal Bupivacaine Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the liposomal bupivacaine market are:
1. FDA Approval and Recognition.
2. Increasing Number of Surgeries.
The liposomal bupivacaine market is expected to grow at a CAGR of 9.3%.
North America region accounts for highest revenue share in liposomal bupivacaine market.
The final report will duly include market size and projection estimates for all the segments from 2021 to 2031, along with a revenue share and compound annual growth rate (%) for the regional/country-wise market wherein 2021-2022 are the historic years, 2023 is considered to be the base year, and the forecast will be provided till 2031, along with CAGR (%).
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023 - 2031).
Sun Pharmaceutical Industries Ltd. and Johnson and Johnson are the major companies operating in the liposomal bupivacaine market.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Liposomal Bupivacaine Market - By Type
1.3.2 Liposomal Bupivacaine Market - By Application
1.3.3 Liposomal Bupivacaine Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LIPOSOMAL BUPIVACAINE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LIPOSOMAL BUPIVACAINE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LIPOSOMAL BUPIVACAINE MARKET - GLOBAL MARKET ANALYSIS
6.1. LIPOSOMAL BUPIVACAINE - GLOBAL MARKET OVERVIEW
6.2. LIPOSOMAL BUPIVACAINE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. LIPOSOMAL BUPIVACAINE MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. 20ML
7.3.1. Overview
7.3.2. 20ml Market Forecast and Analysis
7.4. 10ML
7.4.1. Overview
7.4.2. 10ml Market Forecast and Analysis
8. LIPOSOMAL BUPIVACAINE MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. VETERINARY
8.3.1. Overview
8.3.2. Veterinary Market Forecast and Analysis
8.4. HUMAN
8.4.1. Overview
8.4.2. Human Market Forecast and Analysis
9. LIPOSOMAL BUPIVACAINE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Liposomal Bupivacaine Market Overview
9.1.2 North America Liposomal Bupivacaine Market Forecasts and Analysis
9.1.3 North America Liposomal Bupivacaine Market Forecasts and Analysis - By Type
9.1.4 North America Liposomal Bupivacaine Market Forecasts and Analysis - By Application
9.1.5 North America Liposomal Bupivacaine Market Forecasts and Analysis - By Countries
9.1.5.1 United States Liposomal Bupivacaine Market
9.1.5.1.1 United States Liposomal Bupivacaine Market by Type
9.1.5.1.2 United States Liposomal Bupivacaine Market by Application
9.1.5.2 Canada Liposomal Bupivacaine Market
9.1.5.2.1 Canada Liposomal Bupivacaine Market by Type
9.1.5.2.2 Canada Liposomal Bupivacaine Market by Application
9.1.5.3 Mexico Liposomal Bupivacaine Market
9.1.5.3.1 Mexico Liposomal Bupivacaine Market by Type
9.1.5.3.2 Mexico Liposomal Bupivacaine Market by Application
9.2. EUROPE
9.2.1 Europe Liposomal Bupivacaine Market Overview
9.2.2 Europe Liposomal Bupivacaine Market Forecasts and Analysis
9.2.3 Europe Liposomal Bupivacaine Market Forecasts and Analysis - By Type
9.2.4 Europe Liposomal Bupivacaine Market Forecasts and Analysis - By Application
9.2.5 Europe Liposomal Bupivacaine Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Liposomal Bupivacaine Market
9.2.5.1.1 Germany Liposomal Bupivacaine Market by Type
9.2.5.1.2 Germany Liposomal Bupivacaine Market by Application
9.2.5.2 France Liposomal Bupivacaine Market
9.2.5.2.1 France Liposomal Bupivacaine Market by Type
9.2.5.2.2 France Liposomal Bupivacaine Market by Application
9.2.5.3 Italy Liposomal Bupivacaine Market
9.2.5.3.1 Italy Liposomal Bupivacaine Market by Type
9.2.5.3.2 Italy Liposomal Bupivacaine Market by Application
9.2.5.4 Spain Liposomal Bupivacaine Market
9.2.5.4.1 Spain Liposomal Bupivacaine Market by Type
9.2.5.4.2 Spain Liposomal Bupivacaine Market by Application
9.2.5.5 United Kingdom Liposomal Bupivacaine Market
9.2.5.5.1 United Kingdom Liposomal Bupivacaine Market by Type
9.2.5.5.2 United Kingdom Liposomal Bupivacaine Market by Application
9.2.5.6 Rest of Europe Liposomal Bupivacaine Market
9.2.5.6.1 Rest of Europe Liposomal Bupivacaine Market by Type
9.2.5.6.2 Rest of Europe Liposomal Bupivacaine Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Liposomal Bupivacaine Market Overview
9.3.2 Asia-Pacific Liposomal Bupivacaine Market Forecasts and Analysis
9.3.3 Asia-Pacific Liposomal Bupivacaine Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Liposomal Bupivacaine Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Liposomal Bupivacaine Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Liposomal Bupivacaine Market
9.3.5.1.1 Australia Liposomal Bupivacaine Market by Type
9.3.5.1.2 Australia Liposomal Bupivacaine Market by Application
9.3.5.2 China Liposomal Bupivacaine Market
9.3.5.2.1 China Liposomal Bupivacaine Market by Type
9.3.5.2.2 China Liposomal Bupivacaine Market by Application
9.3.5.3 India Liposomal Bupivacaine Market
9.3.5.3.1 India Liposomal Bupivacaine Market by Type
9.3.5.3.2 India Liposomal Bupivacaine Market by Application
9.3.5.4 Japan Liposomal Bupivacaine Market
9.3.5.4.1 Japan Liposomal Bupivacaine Market by Type
9.3.5.4.2 Japan Liposomal Bupivacaine Market by Application
9.3.5.5 South Korea Liposomal Bupivacaine Market
9.3.5.5.1 South Korea Liposomal Bupivacaine Market by Type
9.3.5.5.2 South Korea Liposomal Bupivacaine Market by Application
9.3.5.6 Rest of Asia-Pacific Liposomal Bupivacaine Market
9.3.5.6.1 Rest of Asia-Pacific Liposomal Bupivacaine Market by Type
9.3.5.6.2 Rest of Asia-Pacific Liposomal Bupivacaine Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Liposomal Bupivacaine Market Overview
9.4.2 Middle East and Africa Liposomal Bupivacaine Market Forecasts and Analysis
9.4.3 Middle East and Africa Liposomal Bupivacaine Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Liposomal Bupivacaine Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Liposomal Bupivacaine Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Liposomal Bupivacaine Market
9.4.5.1.1 South Africa Liposomal Bupivacaine Market by Type
9.4.5.1.2 South Africa Liposomal Bupivacaine Market by Application
9.4.5.2 Saudi Arabia Liposomal Bupivacaine Market
9.4.5.2.1 Saudi Arabia Liposomal Bupivacaine Market by Type
9.4.5.2.2 Saudi Arabia Liposomal Bupivacaine Market by Application
9.4.5.3 U.A.E Liposomal Bupivacaine Market
9.4.5.3.1 U.A.E Liposomal Bupivacaine Market by Type
9.4.5.3.2 U.A.E Liposomal Bupivacaine Market by Application
9.4.5.4 Rest of Middle East and Africa Liposomal Bupivacaine Market
9.4.5.4.1 Rest of Middle East and Africa Liposomal Bupivacaine Market by Type
9.4.5.4.2 Rest of Middle East and Africa Liposomal Bupivacaine Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Liposomal Bupivacaine Market Overview
9.5.2 South and Central America Liposomal Bupivacaine Market Forecasts and Analysis
9.5.3 South and Central America Liposomal Bupivacaine Market Forecasts and Analysis - By Type
9.5.4 South and Central America Liposomal Bupivacaine Market Forecasts and Analysis - By Application
9.5.5 South and Central America Liposomal Bupivacaine Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Liposomal Bupivacaine Market
9.5.5.1.1 Brazil Liposomal Bupivacaine Market by Type
9.5.5.1.2 Brazil Liposomal Bupivacaine Market by Application
9.5.5.2 Argentina Liposomal Bupivacaine Market
9.5.5.2.1 Argentina Liposomal Bupivacaine Market by Type
9.5.5.2.2 Argentina Liposomal Bupivacaine Market by Application
9.5.5.3 Rest of South and Central America Liposomal Bupivacaine Market
9.5.5.3.1 Rest of South and Central America Liposomal Bupivacaine Market by Type
9.5.5.3.2 Rest of South and Central America Liposomal Bupivacaine Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL LIPOSOMAL BUPIVACAINE MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOINT VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. LIPOSOMAL BUPIVACAINE MARKET, KEY COMPANY PROFILES
12.1. SUN PHARMACEUTICAL INDUSTRIES LTD.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. JOHNSON AND JOHNSON
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MERCK AND CO.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CIPLA, INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. CADILA PHARMACEUTICALS
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SRS PHARMACEUTICALS PVT. LTD.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. EXPAREL
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. PACIRA
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
* Above given report scope is tentative, and may change during the study process as per the research requirement.
* List of companies provided under ‘Company Profile’ chapter is tentative and may change during the course of the study. This list is customizable as per the client requirements.
* Financial information would be provided only for the public companies.
1. Sun Pharmaceutical Industries Ltd.
2. Johnson and Johnson
3. Merck and Co.
4. Cipla, Inc.
5. Cadila Pharmaceuticals
6. SRS Pharmaceuticals Pvt. Ltd.
7. EXPAREL
8. Pacira
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For